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• The Sickle Cell Data Collection (SCDC) 
program is a population-based, longitudinal 
surveillance system for sickle cell disease 
(SCD) that was designed to collect 
information from multiple data sources, 
including newborn screening (NBS).
• The SCDC programs in California and Georgia 
analyzed their NBS data to describe the 
incidence, demographics, and location of 
newborns with SCD in the two states.
• These findings may be used to impact health 
care policies in ways that improve health 
outcomes and health care access for 
individuals with SCD.
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Conclusions
Background and Objectives
• Data collected through the SCDC program can 
be used to identify the locations that are most 
in need of resources to benefit the SCD 
communities, such as knowledgeable health 
care providers, specialty care centers, and 
hospital and emergency facilities.
• These data are critical for understanding 
changes in epidemiology to identify 
opportunities for targeted SCD interventions 
such as:
• workforce development,
• patient education, and 
• care across the lifespan.
Figures
• Data on newborns with confirmed SCD born 
in California or Georgia during 2004 through 
2016 were reported to SCDC by the state NBS 
programs.
• An analysis of sex, race, SCD genotype, and 
county of residence identified temporal 
changes in the SCD populations.
Methods
Acknowledgements
Results – Figure 1
• There were 1,165 babies (annual mean = 90 
babies) with SCD born in California and 
2,025 babies (annual mean = 156 babies) 
with SCD born in Georgia during 2004 
through 2016. 
• 47% (California) and 49% (Georgia) of babies 
were female
• 83% (California) and 94% (Georgia) of babies 
were black or African American
• Across both states, 56-60% of babies had 
hemoglobin S/S or S/b0 thalassemia; 28-30% 
had hemoglobin S/C; 8-10% had hemoglobin 
S/b+ thalassemia; and the remainder had 
other or unknown SCD genotype.
Results – Figure 2
• In California (Figures 2a-b): 
• Approximately 50% of babies lived in two 
counties: Los Angeles and San Bernardino
• Los Angeles County had the highest number of 
babies born with SCD across the years, but this 
number declined by 33% from 2005-2009 to 
2010-2014.
• In Georgia (Figures 2c-d):
• Approximately 50% of babies lived in six 
counties: Fulton, DeKalb, Clayton, Gwinnett, 
Cobb, and Chatham
• Fulton County had the highest number of births 
during 2005-2008 (n=127), but DeKalb County 
had the highest number of births during 2009-
2014 (n=97)
Figure 1: Sickle cell disease (SCD) genotype
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Figure 1a, California
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Figure 2: Counties with the highest number of SCD births
Figure 2a: California, 2005-2009
Figure 2b: California, 2010-2014
Figure 2c: Georgia, 2005-2009
Figure 2d: Georgia, 2010-2014
